Sanofi discontinues clinical development of inve... - MPN Voice

MPN Voice

10,886 members15,202 posts

Sanofi discontinues clinical development of investigational JAK2 agent Fedratinib (SAR302503)

Mazcd profile image
MazcdPartnerMPNVoice
5 Replies

Press release from Sanofi issued 18th November 2013 regarding the decision to halt all clinical trials and development of investigational JAK2 Agent Fedratinib (SAR302503)

Sanofi (EURONEXT: SAN and NYSE: SY) have announced their decision to halt all clinical trials and cancel plans for regulatory filings for the investigational JAK2 inhibitor fedratinib (SAR302503). This is following a risk-benefit analysis following recent reports of cases consistent with *Wernicke’s encephalopathy in patients participating in fedratinib clinical trials.

The press release is available here mpdvoice.org.uk/wp-content/...

Fedratinib is a novel, investigational JAK2 inhibitor that was under development for the treatment of the three main types of MPNs (myeloproliferative neoplasms): primary myelofibrosis (including those patients previously treated with Ruxolitinib) polycythaemia vera and essential thrombocythaemia.

If you are currently in a fedratinib trial you should have been contacted by your haematologist/physician who will determine the best alternative therapies available to you.

If you have any concerns regarding fedratinib please contact your haematologist.

*Wernicke’s encephalopathy – mental confusion or delirium occurring in combination with paralysis of the eye muscles, nystagmus and an unsteady gait.

Written by
Mazcd profile image
Mazcd
Partner
To view profiles and participate in discussions please or .
Read more about...
5 Replies
malachy profile image
malachy

Thanks Maz, such a shame it's not worked out. I wish everyone on the trial good luck in finding a good alternative.

light profile image
light

Do you know what is the reason for stopping this trial for JAK2??

Mazcd profile image
MazcdPartnerMPNVoice in reply tolight

Hi Light, it's because there have been some cases of people on the trial suffering with Wernicke’s encephalopathy – mental confusion or delirium occurring in combination with paralysis of the eye muscles, nystagmus and an unsteady gait, therefore the trial has been stopped while investigations are carried out. Maz

light profile image
light in reply toMazcd

Thanks Maz, it is good to know that. Do you have any more of information on that investigations? How long they are going to go with it and whether they will share findings from that investigation and would that be available to us??

Mazcd profile image
MazcdPartnerMPNVoice

Hi Light, I'm sorry but I don't know any more than has been published in the press release, as per the link in my post above, as soon as any further information is released I will let you know.

Not what you're looking for?

You may also like...

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia

 »The variant allele frequency (VAF) of driver mutations (JAK2, CALR) in myeloproliferative...
Manouche profile image

Did your fatigue diminish when you switched from hydroxyurea to a JAK2 inhibitor such as ruxolitinib?

Did your fatigue diminish when you switched from hydroxyurea to a JAK2 inhibitor such as...
TLJ-1 profile image

Blood cancers: New generation stem cell transplant significantly reduces complications for patients

Post by MPN-MATE Admin » Wed Nov 06, 2019 9:21 am Hey everyone... :-) More great good news is...
socrates_8 profile image

FDA Approves Ropeginterferon Alfa-2b-njft for Polycythemia Vera

The FDA has approved ropeginterferon alfa-2b-njft (Besremi) for use as a treatment in patients...
JT_Marlin profile image

Ropeg versus HU/BAT results after 3 years

This is very interesting summary of trial results after 3 years. (CHR is Complete Haematological...
Paul123456 profile image

Moderation team

Debinha profile image
DebinhaAdministrator
Mazcd profile image
MazcdPartner

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.